Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial (Abstract S3-7; Hortobagyi G et al.)
RPC de Nice St Paul. Veille Bibliographique et Mise à Jour des Traitements Adjuvants systémiques des Cancers du sein. (Sous l’égide de la FFOM).
Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus Tamoxifen in the TEAM pathology sub-study . JMS BARTLETT et al
Neoadjuvant chemotherapy of Paclitaxel with or without Rad001: results of the non-responder part of the GEPARQUINTO study (GBG 44) (Abstract S3-6; Huober J et al.)
